Taspoglutide

Taspoglutide

Clinical data
Routes of administration	subcutaneous
ATC code	none
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS Number	275371-94-3 N
ChemSpider	none
UNII	2PHK27IP3B Y
Chemical and physical data
Formula	C152H232N40O45
Molar mass	3339.75 g/mol
NY (what is this?)  (verify)

Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.^{[1] [2]}

Two phase II trials reported it was effective and well tolerated.^[3]

Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.^[4] Preliminary results in early 2010 were favourable.^[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.^[6])

In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.^[7][8]

As of May 2013 no new trials had been registered.^[9]

Chemistry

Taspoglutide is the peptide with the sequence H₂N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH₂.

In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.

See also

• Glucagon-like peptide-1 analogs:

exenatide (Byetta)

liraglutide (Victoza)

albiglutide

• DPP4 inhibitors
• Incretin

References